Drug Profile
Diphtheria, tetanus and pertussis vaccine - Tianjin CanSino Biotechnology
Alternative Names: Component pertussis based adult and adolescent vaccine; Tdcp adolescent and adult - Tianjin CanSino Biotechnology; Tdcp vaccineLatest Information Update: 25 Dec 2023
Price :
$50
*
At a glance
- Originator Tianjin CanSino Biotechnology
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Diphtheria; Pertussis; Tetanus
Most Recent Events
- 06 Dec 2023 Phase-I clinical trials in Diphtheria (Prevention, In children, In adults, In the elderly, In adolescents) in China (Parenteral) (NCT06056050)
- 06 Dec 2023 Phase-I clinical trials in Pertussis (Prevention, In children, In adults, In the elderly, In adolescents) in China (Parenteral) (NCT06056050)
- 06 Dec 2023 Phase-I clinical trials in Tetanus (Prevention, In adults, In children, In the elderly, In adolescents) in China (Parenteral) (NCT06056050)